v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue:    
License and collaboration revenue $ 10,000 $ 5,000
Total revenue 10,000 5,000
Operating expenses:    
Research and development 168,063 139,139
General and administrative 53,322 29,749
Acquired in-process research and development 171,672  
Total operating expenses 393,057 168,888
Loss from operations (383,057) (163,888)
Other income (expense), net:    
Fair value adjustments to convertible notes   (846)
Interest expense on royalty obligation (7,327)  
Interest income 12,151 7,973
Other income, net 417 202
Total other income (expense), net 5,241 7,329
Loss before income taxes (377,816) (156,559)
Income tax (benefit) provision (79) 429
Net loss $ (377,737) $ (156,988)
Net loss per share - basic (in dollars per share) $ (8.44) $ (11.89)
Net loss per share - diluted (in dollars per share) $ (8.44) $ (11.89)
Weighted-average common stock outstanding - basic (in shares) 44,730,052 13,198,960
Weighted-average common stock outstanding - diluted (in shares) 44,730,052 13,198,960
Comprehensive loss:    
Net loss $ (377,737) $ (156,988)
Other comprehensive income (loss):    
Unrealized gain on investments 156 31
Foreign currency translation adjustment (414) 126
Comprehensive loss $ (377,995) $ (156,831)